Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|May 28, 2026
Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM PatientsVinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, et al.Journal of Experimental & Clinical Cancer Research : CR|November 3, 2012
The cost of unresectable stage III or stage IV melanoma in ItalyMichele Maio, Paolo Ascierto, Alessandro Testori, et al.The Journal of Allergy and Clinical Immunology. Global|January 8, 2024
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitisBarbara Rewerska, Lawrence D Sher, Sady Alpizar, et al.The Lancet. Oncology|April 5, 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.Lancet (London, England)|December 14, 2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Charlotte Graham, Deborah Yallop, et al.Nature Cancer|September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cellsLaura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.Pageof 1